Jubilant Pharmova’s step down arm signs, issues put option offer to Pierre Fabre Laboratories

19 Aug 2024 Evaluate

Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Biosys’ (JBL) subsidiary -- Jubilant Biosys Innovative Research Services Pte, Singapore has signed and issued a ‘put option offer’ to Pierre Fabre Laboratories, which sets forth an offer to acquire 80% equity capital (around Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre’s R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France.

The R&D centre has a capability of conducting discovery and preclinical development activities in immune-oncology. The facilities include research labs & office space including parking area surrounded by green field.

Pierre Fabre Laboratories may invest 20% equity capital (around Euro 1.1 million over a period of 2 years) in a new company for a maximum period of 5 years, during which time they may continue to provide support to the new company. In addition to that, Pierre Fabre Laboratories may also hire services from Jubilant Biosys aggregating to Euro 7 million for first 4 years post-closing date.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

1063.05 -29.15 (-2.67%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.